Although no significant changes in leptin or adiponectin levels have been observed in studies of IF in MS, an observed difference in T-cell subsets in intestines might explain the immunological effects of IF that have been reported in studies (33, 60), which was also a kind of possible therapy for MS (59). Here, ADIPOQ is linked to myeloid sarcoma.